Kintara Therapeutics, Inc. KTRA
We take great care to ensure that the data presented and summarized in this overview for Kintara Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in KTRA
Top Purchases
Top Sells
About KTRA
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
Insider Transactions at KTRA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 18
2024
|
James A. Bianco Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,323,307
+50.0%
|
-
|
|
Jun 01
2023
|
Robert E. Hoffman President, CEO and Interim CFO |
BUY
Grant, award, or other acquisition
|
Direct |
59,800
+46.46%
|
-
|
|
Jan 05
2023
|
Dennis M Brown Chief Scientific Officer |
BUY
Acquisition or disposition by will or laws
|
Direct |
363
+6.41%
|
-
|
|
Aug 01
2022
|
Anthony Scott Praill Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
240,087
+46.41%
|
-
|
|
Aug 01
2022
|
Robert E. Hoffman President, CEO and Interim CFO |
BUY
Grant, award, or other acquisition
|
Direct |
400,145
+46.78%
|
-
|
|
Aug 01
2022
|
Dennis M Brown Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
240,087
+49.3%
|
-
|
|
Feb 15
2022
|
Robert E. Hoffman President, CEO and Interim CFO |
BUY
Open market or private purchase
|
Direct |
55,000
+50.0%
|
$0
$0.47 P/Share
|
|
Dec 08
2021
|
Anthony Scott Praill Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
28,700
+43.56%
|
$0
$0.68 P/Share
|
|
Dec 07
2021
|
Saiid Zarrabian Head of Strategic Partnerships |
BUY
Open market or private purchase
|
Direct |
38,109
+40.71%
|
$0
$0.64 P/Share
|
|
Dec 06
2021
|
Saiid Zarrabian Head of Strategic Partnerships |
BUY
Open market or private purchase
|
Direct |
11,891
+40.61%
|
$0
$0.59 P/Share
|
|
Nov 22
2021
|
Laura L. Johnson Director |
BUY
Open market or private purchase
|
Direct |
3,000
+50.0%
|
$0
$0.74 P/Share
|
|
Apr 29
2021
|
Robert Joseph Toth Jr Director |
BUY
Conversion of derivative security
|
Direct |
325
+17.19%
|
-
|
|
Apr 29
2021
|
Robert Joseph Toth Jr Director |
BUY
Other acquisition or disposition
|
Direct |
3
+0.24%
|
-
|
|
Apr 29
2021
|
Anthony Scott Praill Chief Financial Officer |
BUY
Conversion of derivative security
|
Direct |
938
+9.95%
|
-
|
|
Apr 29
2021
|
Anthony Scott Praill Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
8
+0.11%
|
-
|
|
Apr 29
2021
|
Dennis M Brown Chief Scientific Officer |
BUY
Conversion of derivative security
|
Direct |
750
+9.91%
|
-
|
|
Apr 29
2021
|
Dennis M Brown Chief Scientific Officer |
BUY
Other acquisition or disposition
|
Direct |
6
+0.1%
|
-
|
|
Mar 31
2021
|
Anthony Scott Praill Chief Financial Officer |
BUY
Other acquisition or disposition
|
Direct |
22
+0.29%
|
-
|
|
Mar 31
2021
|
Dennis M Brown Chief Scientific Officer |
BUY
Other acquisition or disposition
|
Direct |
17
+0.28%
|
-
|
|
Mar 31
2021
|
Robert Joseph Toth Jr Director |
BUY
Other acquisition or disposition
|
Direct |
8
+0.64%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 2.32M shares |
|---|